For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of ...

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Healthcare stocks to watch in Q2 earnings: overbought RSI leaders like CRNX, APGE, TECH and more, plus top healthcare ETFs.

Will Kane joined Malvern-based Uniquity Bio as President and CEO in 2025. A Malvern biotech with a drug targeting some of the world’s most common respiratory and digestive diseases is gearing up to ...

Scancell Holdings and Neuphoria Therapeutics have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders afte | ...

"I can't even sell it — please, someone save me," said one retail investor in Kolon TissueGene. "It's completely finished," ...

Biotechnology investors remain confident in the sector's outlook even after a major comeback this year — and they're picking ...

Despite stock dips, the Minnesota biotech firm thinks its innovative therapy and strong results can compete in multibillion ...

BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. There’s no doubt that biotech IPOs are back. After a prolonged ...

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese ...

Biotech has been misunderstood as inherently risky for years. But that is no longer the case, says Ailsa Craig.